- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00188695
Combidex USPIO - Ultra-small Superparamagnetic Iron Oxide
October 6, 2022 updated by: University Health Network, Toronto
A Pilot Study of MR Imaging With Ultra-small Superparamagnetic Iron Oxide for Pelvic Lymph Node Target Definition
The purpose of this study is to test whether or not a new contrast agent called Combidex, a contrast agent formulated from ultra-small superparamagnetic iron oxide (USPIO) improves the ability of Magnetic Resonance Imaging (MRI) to see lymph nodes in the pelvis.
It might also help doctors tell whether or not cancer has spread to these lymph nodes.
It might allow radiotherapy to be delivered more accurately.
Study Overview
Status
Completed
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
61
Phase
- Phase 2
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ontario
-
Toronto, Ontario, Canada, M5G 2M9
- Princess Margaret Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- histologically confirmed endometrial, cervix, prostate (cT1-cT3) or bladder cancer
- no distant metastases
- informed consent
Exclusion Criteria:
- confirmed prostate carcinoma and PSA less than or equal to 4 or greater than 100
- radical surgery or prior cryosurgery for prostate carcinoma, previous RT, hormonal manipulation or chemotherapy
- biopsy-proven lymph node involvement
- endometrium or cervix carcinoma who have undergone recent pelvic surgery with the exclusion of D&C or biopsy
- bladder carcinoma with recent pelvic surgery with the exclusion of TURBT
- previous or concurrent cancers other than superficial basal or squamous cell skin carcinoma unless disease-free for at least 5 yrs
- contraindication to MR imaging
- hip prosthesis
- major medical or psychiatric illness
- patients with known allergy to dextran or iron-containing compounds
- patients with cirrhosis or hemochromatosis
- patients receiving another MR contrast within 2 hrs prior to the ferumoxtran-10
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Diagnostic
- Allocation: Non-Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Improved delineation of normal pelvic lymph nodes in patients with uterine, cervical, bladder and prostate cancers.
Time Frame: once at time of imaging
|
once at time of imaging
|
|
Improved clinical target volume (CTV) definition for the purpose of adjuvant irradiation of pelvic lymph nodes using intensity modulated radiotherapy (IMRT).
Time Frame: once at time of imaging
|
once at time of imaging
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Comparison of target lymph node delineation between nodal imaging with USPIO and volume expansion of vascular anatomy.
Time Frame: once at time of imaging
|
once at time of imaging
|
|
Demonstration of the pattern and distribution of pelvic nodal metastases in patients with uterine, cervical, bladder and prostate cancers.
Time Frame: once at time of imaging
|
once at time of imaging
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Collaborators
Investigators
- Principal Investigator: Michael Milosevic, MD, Princess Margaret Hospital, Canada
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 1, 2004
Primary Completion (Actual)
June 1, 2006
Study Completion (Actual)
March 15, 2022
Study Registration Dates
First Submitted
September 12, 2005
First Submitted That Met QC Criteria
September 12, 2005
First Posted (Estimate)
September 16, 2005
Study Record Updates
Last Update Posted (Actual)
October 7, 2022
Last Update Submitted That Met QC Criteria
October 6, 2022
Last Verified
October 1, 2022
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Urologic Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Urologic Diseases
- Urinary Bladder Diseases
- Genital Neoplasms, Female
- Uterine Cervical Diseases
- Uterine Diseases
- Genital Neoplasms, Male
- Prostatic Diseases
- Neoplasms
- Uterine Cervical Neoplasms
- Prostatic Neoplasms
- Urinary Bladder Neoplasms
- Uterine Neoplasms
Other Study ID Numbers
- 03-0838-C
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.